{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010529","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.673321+00:00","generated_at":"2026-05-31T13:49:31.124223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"uniQure Q2 net loss $56.3M; restructures to cut 65% of workforce, burn by $75M/yr","bullets":["Net loss $56.3M ($1.16 EPS) vs $68.5M ($1.44 EPS) in Q2 2023; revenue $11.1M up from $2.4M.","Restructuring: 65% headcount reduction (~300 roles), sale of Lexington facility, $75M annual cash burn cut including $50M debt retirement.","Cash $524M as of June 30, expected to fund operations through end 2027.","FDA granted RMAT designation for AMT-130 in Huntington's; interim data showed dose-dependent slowing of disease progression and reduced NfL.","Patient screening started for three new Phase I/II trials (AMT-260 mTLE, AMT-191 Fabry, AMT-162 SOD1 ALS); enrollment expected Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010529","json":"https://secwatch.observer/filing/0001558370-24-010529.json","markdown":"https://secwatch.observer/filing/0001558370-24-010529.md","text":"https://secwatch.observer/filing/0001558370-24-010529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024010529/0001558370-24-010529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024010529/qure-20240801x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:49:31.124223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}